Oncternal Therapeutics, Inc. (ONCT): Price and Financial Metrics


Oncternal Therapeutics, Inc. (ONCT): $1.18

0.02 (+1.58%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ONCT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ONCT POWR Grades

  • ONCT scores best on the Sentiment dimension, with a Sentiment rank ahead of 94.38% of US stocks.
  • ONCT's strongest trending metric is Value; it's been moving down over the last 177 days.
  • ONCT ranks lowest in Momentum; there it ranks in the 5th percentile.

ONCT Stock Summary

  • The ratio of debt to operating expenses for ONCTERNAL THERAPEUTICS INC is higher than it is for about only 4.42% of US stocks.
  • With a price/sales ratio of 34.85, ONCTERNAL THERAPEUTICS INC has a higher such ratio than 95.58% of stocks in our set.
  • As for revenue growth, note that ONCT's revenue has grown -64.93% over the past 12 months; that beats the revenue growth of just 2.79% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to ONCTERNAL THERAPEUTICS INC are AEVA, EXAI, CARA, PRTA, and CUE.
  • Visit ONCT's SEC page to see the company's official filings. To visit the company's web site, go to www.oncternal.com.

ONCT Valuation Summary

  • In comparison to the median Healthcare stock, ONCT's EV/EBIT ratio is 98.99% lower, now standing at 0.1.
  • Over the past 231 months, ONCT's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for ONCT.

Stock Date P/S P/B P/E EV/EBIT
ONCT 2023-01-20 35.1 1.0 -1.6 0.1
ONCT 2023-01-19 36.1 1.0 -1.7 0.1
ONCT 2023-01-18 37.3 1.0 -1.7 0.0
ONCT 2023-01-17 39.0 1.1 -1.8 -0.1
ONCT 2023-01-13 38.8 1.1 -1.8 -0.1
ONCT 2023-01-12 38.1 1.0 -1.8 0.0

ONCT Growth Metrics

    The 3 year price growth rate now stands at -86.09%.
  • Its year over year price growth rate is now at -79.82%.
  • Its 5 year net cashflow from operations growth rate is now at 34.97%.
Over the past 18 months, ONCT's revenue has gone down $1,669,000.

The table below shows ONCT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 1.875 -34.318 -40.843
2022-06-30 3.621 -28.732 -39.348
2022-03-31 4.313 -29.21 -35.289
2021-12-31 4.315 -26.589 -31.333
2021-09-30 5.347 -23.884 -25.817
2021-06-30 3.804 -22.831 -20.582

ONCT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ONCT has a Quality Grade of D, ranking ahead of 14.56% of graded US stocks.
  • ONCT's asset turnover comes in at 0.042 -- ranking 334th of 682 Pharmaceutical Products stocks.
  • CPRX, CHRS, and XTNT are the stocks whose asset turnover ratios are most correlated with ONCT.

The table below shows ONCT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.042 1 6.705
2021-03-31 0.051 1 4.190
2020-12-31 0.075 1 3.387
2020-12-31 0.075 1 3.387
2020-09-30 0.123 1 3.414
2020-06-30 0.119 1 3.551

ONCT Price Target

For more insight on analysts targets of ONCT, see our ONCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $15.50 Average Broker Recommendation 1.38 (Strong Buy)

ONCT Stock Price Chart Interactive Chart >

Price chart for ONCT

ONCT Price/Volume Stats

Current price $1.18 52-week high $2.20
Prev. close $1.16 52-week low $0.69
Day low $1.14 Volume 92,400
Day high $1.18 Avg. volume 261,917
50-day MA $1.04 Dividend yield N/A
200-day MA $1.06 Market Cap 66.38M

Oncternal Therapeutics, Inc. (ONCT) Company Bio


Oncternal Therapeutics (formerly GTx, Inc.), a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other serious medical conditions. The company was founded in 1997 and is based in Memphis, Tennessee.


ONCT Latest News Stream


Event/Time News Detail
Loading, please wait...

ONCT Latest Social Stream


Loading social stream, please wait...

View Full ONCT Social Stream

Latest ONCT News From Around the Web

Below are the latest news stories about ONCTERNAL THERAPEUTICS INC that investors may wish to consider to help them evaluate ONCT as an investment opportunity.

Oncternal Therapeutics Announces the Appointment of Jill DeSimone to the Board of Directors

SAN DIEGO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Jill DeSimone to its board of directors. “We are thrilled to have Jill join the Oncternal board of directors. Jill’s accomplishments building a multi-billion dollar oncology business in the U.S. are a great fit for supporting Oncternal’s transition into a late-stage oncology

Yahoo | January 4, 2023

Oncternal Therapeutics Reports Granting of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it has granted inducement awards to two new non-executive employees. The awards were made on January 3, 2023 under Oncternal’s 2021 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Oncternal as an inducement to join the Compan

Yahoo | January 3, 2023

Investing in Oncternal Therapeutics Inc. (ONCT) might be a great opportunity, but the stock is a bit overvalued

As of Friday, Oncternal Therapeutics Inc.’s (NASDAQ:ONCT) stock closed at $0.96, up from $0.91 the previous day. While Oncternal Therapeutics Inc. has overperformed by 5.94%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ONCT fell by -63.17%, with highs and lows ranging from $2.69 to $0.69, […]

US Post News | December 26, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a look at the biggest pre-market stock movers traders need to know about for Monday morning!

William White on InvestorPlace | December 12, 2022

The Battle of Fundamentals and Techniques: Oncternal Therapeutics Inc. (ONCT)

Oncternal Therapeutics Inc. (ONCT)’s stock has witnessed a price declined of -7.49% from the previous close with its current price standing at $0.99. Its current price is -65.51% under its 52-week high of $2.87 and 43.42% more than its 52-week low of $0.69. Based on the past 30-day period, the stock price is -15.25% below […]

US Post News | December 12, 2022

Read More 'ONCT' Stories Here

ONCT Price Returns

1-mo 26.30%
3-mo 10.28%
6-mo 14.56%
1-year -29.34%
3-year -70.08%
5-year -98.82%
YTD 18.00%
2022 -55.95%
2021 -53.67%
2020 24.05%
2019 -27.66%
2018 -93.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8379 seconds.